Effects of systemic administration of sitafloxacin on subgingival microflora and antimicrobial susceptibility profile in acute periodontal lesions

Microbiological and Clinical Effects of Sitafloxacin and Azithromycin in Periodontitis Patients Receiving Supportive Periodontal Therapy

“…The MIC 90 for STFX (0.12 to 0.25 g/ml) was lower than the concentration of STFX in GCF (mean, 1.20 g/ml) in both the STFX and AZM groups at baseline and 1 month, suggesting good antimicrobial activity of STFX in periodontal lesions. The excellent antimicrobial activity was confirmed by the study showing that the MIC 90 for clinical isolates from acute periodontal lesions was very low for STFX (0.12 g/ ml) (14). On the other hand, the MIC 90 for AZM was comparable to or higher than the concentration of AZM in GCF.…”

“…We previously reported that oral administration of STFX in patients receiving supportive periodontal therapy was microbiologically and clinically as effective as scaling and root planing under local anesthesia over a 3-month period (13). Recently, Tomita et al demonstrated that STFX was the most potent against the clinical isolates from acute periodontal lesions among the antimicrobials tested (14). Therefore, it is suggested that this drug may be useful for longer maintenance of residual periodontal pockets without exacerbation.…”

Changes in antimicrobial susceptibility profile and prevalence of quinolone low-sensitive strains in subgingival plaque from acute periodontal lesions after systemic administration of sitafloxacin

“…This study is a follow-up of a previously reported study in which we assessed the effects of systemic administration of sitafloxacin on subgingival microbial profiles of acute periodontal lesions [12]. Study participants were consecutively recruited from patients who visited the Conservative Dentistry, Tokyo Dental College Chiba Hospital (Chiba, Japan) or Dentistry and Oral Surgery, Keio University Hospital (Tokyo, Japan) during the period of March 2012 through May 2013.…”

“…Patients were asked to participate if they were diagnosed with acute phase of chronic periodontitis [13]. Criteria for the acute phase included at least two of the following clinical signs or symptoms; pain, swelling, redness or a feeling of warmth in the periodontal lesion [12]. Exclusion criteria included uncontrolled systemic diseases, history of allergic reaction to antimicrobial agents, history of antimicrobial or anti-inflammatory therapy in the previous 6 months, <30 years of age, pregnant or lactating women [12].…”

“…Sitafloxacin has also been shown to effectively suppress the major periodontal pathogens such as Porphyromonas gingivalis, Treponema denticola and Tannerella forsythia in elderly patients receiving supportive periodontal therapy [11]. In a previous study, we reported that systemic administration of sitafloxacin exhibited potent antimicrobial activity against majority of subgingival bacteria isolated from acute periodontal lesions [12]. Currently information is limited regarding the longitudinal change in susceptibility profile of periodontal bacteria following antimicrobial therapy in patients with periodontitis.…”